Your session is about to expire
← Back to Search
Central vs Brachial Blood Pressure Targeting for Chronic Kidney Disease (CENTRAL-CKD Trial)
N/A
Recruiting
Led By Remi Goupil, MD MSc
Research Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Over 18 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
CENTRAL-CKD Trial Summary
This trial is designed to compare the feasibility and effectiveness of targeting central BP in advanced CKD patients as opposed to brachial cuff BP.
Who is the study for?
This trial is for adults over 18 with advanced chronic kidney disease (CKD stages 4 and 5) who have an eGFR <30 mL/min/1.73m2 and a systolic blood pressure between 120-160 mmHg. It's not for those on more than four blood pressure meds, recently hospitalized for heart issues or falls, or likely to die within six months.Check my eligibility
What is being tested?
The CENTRAL-CKD trial tests if targeting central blood pressure rather than the usual arm cuff measurement can better manage high blood pressure in CKD patients. Participants are randomly assigned to one of two groups: one aiming for a central BP target under 130 mmHg, the other sticking to standard brachial BP targets.See study design
What are the potential side effects?
Since this study focuses on measuring techniques rather than new medications, side effects may be related to changes in existing hypertension treatment regimens as directed by doctors but are not directly caused by the intervention itself.
CENTRAL-CKD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am over 18 years old.
CENTRAL-CKD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Difference in aortic stiffness
Feasibility: Achieved BP target rate
Feasibility: Completion rate
+5 moreSecondary outcome measures
Change in albuminuria
Difference in Daily Defined Doses of blood pressure drugs
Difference in eGFR decline
+1 moreOther outcome measures
Acute kidney injury (>50% increase in serum creatinine)
All-cause hospitalisation
All-cause mortality
+3 moreCENTRAL-CKD Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Central BP targetExperimental Treatment1 Intervention
Participants randomized to central BP target will be treated with anti-hypertensive agents to achieve a clinic central SBP < 130 mmHg.
Group II: Brachial BP target (standard of care)Active Control1 Intervention
Participants randomized to a brachial BP target will be treated with anti-hypertensive drugs to achieve a clinic brachial SBP <130 mmHg.
Find a Location
Who is running the clinical trial?
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealLead Sponsor
12 Previous Clinical Trials
4,225 Total Patients Enrolled
Remi Goupil, MD MScPrincipal InvestigatorHôpital Sacré-Coeur de Montréal
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not willing to change my blood pressure medication.I cannot give consent because of cognitive issues.I was hospitalized due to a fall in the last 30 days.You are currently involved in another study that may affect your blood pressure levels.My kidney function has worsened significantly in the last month.I have not had a heart attack, stroke, or heart failure in the last 30 days.I am currently taking 5 or more medications for high blood pressure.I have had a kidney transplant or been on dialysis.I am over 18 years old.I do not have any major illness that could lead to death within 6 months.Your blood pressure is between 120 and 160 when measured in the doctor's office using an automated blood pressure machine.My kidney function is low, with an eGFR below 30.
Research Study Groups:
This trial has the following groups:- Group 1: Brachial BP target (standard of care)
- Group 2: Central BP target
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is access to this experiment still available for participants?
"Affirmative. Clinicaltrials.gov contains information which detects that this clinical trial, initially posted on May 24th 2022, is now recruiting patients. Approximately 116 participants are required from a single site to partake in the study."
Answered by AI
To what extent is the current medical trial recruiting participants?
"Affirmative. According to clinicaltrials.gov, this research endeavour was posted on the 24th of May 2022 and modified recently on the 18th of July 2022; it is currently looking for 116 participants across a single site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger